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Angiogenesis is an important physiological process where new blood vessels are 
formed from already existing blood vessels unlike vasculogenesis, which involves 
formation of blood vessels de novo. It plays an essential role in growth of tumors and 
development of metastasis. This process involves activation, migration and proliferation 
of endothelial cells and is regulated by specific growth factors. Ultrasound is an ideal 
imaging modality that enables scanning in real-time with the help of ultrasound contrast 
agents. When the gas-filled, shell stabilized microbubbles of ultrasound contrast agents 
are insonified by an ultrasound beam, they exhibit nonlinear scattering and emit harmonic 
components of the fundamental signal in the received echoes. Utilizing the subharmonic 
component emitted at half of the fundamental frequency (f0/2) provides an improved 
contrast to tissue ratio for ultrasound imaging of tumor angiogenesis. 	  
This project compares quantiﬁable measures of tumor vascularity obtained from 
contrast-enhanced high frequency (HF) and low frequency (LF) subharmonic ultrasound 
imaging (SHI) to 3 immunohistochemical markers of angiogenesis in a murine breast 
cancer model.	  
Nineteen athymic, nude, female rats were implanted with 5×106 breast cancer 
cells (MDA-MB-231) in the mammary fat pad. The contrast agent Definity (Lantheus 
Medical Imaging, N Billerica, MA) was injected in a tail vein (dose: 200 µl/kg) and low 
xii	  
	  
frequency pulse-inversion SHI was performed with a modified Sonix RP scanner 
(Ultrasonix Imaging, Richmond, BC, Canada) using a L9-4 linear array (transmitting at 8 
MHz and receiving at 4 MHz in SHI mode) followed by high frequency imaging with a 
micro-ultrasound scanner, Vevo 2100 (Visual Sonics, Toronto, ON, Canada) using a MS-
250 linear array transducer transmitting and receiving at 24 MHz in Nonlinear Contrast 
mode. The radiofrequency image data was filtered using an IIR Butterworth bandpass 
filter (11-13MHz) to isolate the subharmonic signal (from linear tissue and bubble 
signals). After the experiments, specimens were stained for endothelial cells (CD31), 
vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2). Fractional 
tumor vascularity was calculated as contrast enhanced pixels over tumor area for SHI 
digital images, while the relative area stained over the tumor was calculated from 
specimens. Results were compared on per ROI basis using linear regression analysis.	  
Out of 19 rats, 16 showed tumor growth (84%) and 11 of them were successfully 
imaged. HF SHI demonstrated better resolution but weaker signals than LF SHI. The 
strongest correlation determined by linear regression in this breast cancer model was 
between HF SHI and percent area stained with VEGF (r = 0.38; p=0.034), while there 
was a trend towards significance for HF SHI vs. CD31 and for LF SHI vs. COX-2 
(r~0.31; 0.07<p<0.09).  	  
Quantifiable measures of tumor neovascularity derived from contrast-enhanced 
HF SHI appear to be a better method than LF SHI for monitoring angiogenesis in a breast 
cancer model of murine xenografts (corresponding in particular to the expression of 
VEGF); albeit based on a limited sample size.	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1. INTRODUCTION 
	  
	  
	  
1.1 An Overview 	  
Angiogenesis is a vital physiological process. It consists of development of new 
vasculature from pre-existing blood vessels unlike vasculogenesis which consists of 
formation of the first primitive vascular plexus de novo Angiogenesis is also an essential 
step in the growth of malignant tumors growing beyond 1-2 mm3 and for the 
development of metastases [1-4]. This process is a cascade of several events in which 
host endothelial cells are stimulated to obtain oxygen and blood supply for vascular -in-
growth [5]. It thus provides a pathway for cancer cells to spread via the blood and lymph 
system [6-8]. 	  
Tumors are able to stimulate angiogenesis by directly secreting angiogenic 
substances or activating and releasing angiogenic compounds in extracellular matrix [9]. 
This process involves activation, migration and proliferation of endothelial cells and is 
regulated by specific growth factors [9].  Vascular endothelial growth factor (VEGF) is 
an important angiogenic factor that promotes the growth of tumor by forming immature, 
tortuous and leaky blood vessels [3]. Platelet endothelial cell adhesion molecule 
(PECAM-1 or CD31), a monocyte found on the surface of endothelial cell junctions is 
also a potential endothelial cell marker for angiogenesis [10]. Cyclooxygenase-2 (COX-
2) is another molecule that may be involved in expansion and proliferation of tumor and 
hence could be a positive regulator of angiogenesis [11]. 	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There is an increased interest in non-invasive imaging of tumors to monitor the 
process of angiogenesis so as to evaluate the response of antiangiogenic agents and 
therapies. Ultrasound is an ideal imaging modality which offers scanning in real-time 
with lower cost relative to other imaging modalities and even eliminates ionizing 
radiations [12]. It can provide information related to angiogenesis by measuring tumor 
flow and vascular volume [9]. Conventional Doppler imaging cannot visualize vessels 
smaller than 100 µm [13] and hence, very few ultrasound data is available on the early 
stages of angiogenesis where vessel size is in the range of 20-39 µm [14]. However, the 
use of ultrasound contrast agents improves the signal to noise ratio up to 25 dB and allow 
imaging of neovasculature associated with cancers [15-17]. The gas-filled and shell 
stabilized microbubbles of these contrast agents yield differences in acoustic impedance 
and compressibility relative to the surrounding tissue [13]. 	  
At higher acoustic pressure (>0.5 MPa) these ultrasound contrast agents show 
nonlinear behavior by producing harmonics (ranging from subharmonics to ultra 
harmonic) frequency components in their received echoes. These nonlinear components 
can be used to improve the contrast relative to the surrounding tissue while imaging [18]. 
Harmonic imaging is one such commercially available nonlinear imaging technique, 
which utilizes the second harmonic frequency component from the backscattered echoes 
to improve contrast visualization [18]. However, this technique suffers from 
accumulation of the received harmonic signal in the tissue, which subsequently reduces 
blood to tissue contrast [18]. Subharmonic imaging, wherein the echoes of the signal are 
received at half the fundamental frequency was used as a substitute to harmonic imaging, 
since the subharmonic signal components in the received echoes did not accumulate in 
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the tissue and could be used even at higher frequencies [19]. There have been several in 
vitro as well as in vivo studies reported that showed feasibility of subharmonic ultrasound 
imaging [19-22].  Further improvement in subharmonic imaging is achieved by using 
pulse inversion technique where two consecutive pulses are fired, with second pulse 
being inverted in phase with respect to the previous pulse [23]. This technique cancels 
out the odd harmonics arising from the linear echo components (including linear 
scattering from tissue) and enhances the even harmonics, thus improving the contrast 
detection. 	  
The first use of subharmonic imaging at high frequency was described by Goertz 
et al. in 2005. Their group conducted in vitro studies using wall less phantoms and 
showed a higher contrast to tissue ratio for subharmonic imaging (26 dB vs. 5 dB) as 
compared to conventional harmonic imaging. They also conducted in vivo experiments 
on rabbit ear and mouse heart to demonstrate the feasibility of performing subharmonic 
imaging at a transmit frequency of 20 MHz [24].  Following these studies, there were 
more in vitro and in vivo studies conducted, that used high frequency subharmonic 
imaging [25-27]. However, this method (HF SHI) has not yet been employed to measure 
the tumor vascularity in angiogenesis. This thesis work intends to compare measures of 
tumor vascularity derived from subharmonic imaging with low and high frequency 
ultrasound to the molecular markers of angiogenesis in a murine xenograft model.  
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1.2 Thesis objective(s)	  
The objective of this thesis work is to compare two ultrasound imaging techniques 
(classified on their transmit frequencies) i.e., contrast-enhanced high frequency 
subharmonic imaging (HF SHI) and low frequency subharmonic imaging (LF SHI) and 
investigate which one is a better method to depict tumor angiogenesis noninvasively. 
Towards this objective we use a strategy consisting of three specific aims. 	  
Specific Aim 1: To obtain ultrasound images of rat tumors using low frequency and 
high frequency ultrasound.	  
Subharmonic ultrasound imaging has been used extensively for in vitro as well as in vivo 
studies related to cancer [19-22]. Subharmonic imaging at high frequencies (>20 MHz) 
provides improved image resolution as compared to low frequency imaging and is able to 
depict the blood flow within microvasculature of small anatomical structures [28, 29]. 
However, it has not yet been used to image the tumor angiogenesis in a murine breast 
cancer model. We hypothesized that; using a scanner at transmit frequency of 8MHz and 
receiving ultrasound echoes at 4 MHz (subharmonic frequency) could provide low 
frequency subharmonic scans that would show tumors grown in a murine model of breast 
cancer and scanner at higher transmit frequency (24 MHz) would provide high frequency 
image scans of the same rat tumors, with higher resolution but with weaker signals and 
hence resulting in reduced imaging depth as compared to LF SHI. 
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Specific Aim 2: To optimize High frequency subharmonic ultrasound imaging. 	  
The images acquired from the high frequency scanner would be at the same transmit and 
receive frequency (24 MHz). It is necessary to extract the subharmonic component from 
the RF signal corresponding to the RF data for the acquired high frequency scans. We 
hypothesized that the RF data corresponding to the high frequency image scans could be 
filtered to extract the subharmonic frequency component from the RF signal 
corresponding to the image data, so as to obtain high frequency subharmonic images of 
the tumors.  	  
Specific Aim 3: To compare fractional vascularity (FV) measures obtained from LF 
SHI and HF SHI with FV obtained from pathological tumor specimens stained for 
three immunohistochemical markers. 	  
Three immunohistochemical markers which contribute to the progression of tumor 
angiogenesis, vascular endothelial growth factor (VEGF), Platelet endothelial cell 
adhesion molecule (PECAM-1 or CD31) and Cyclooxygenase-2 (COX-2) were selected 
for comparison to the fractional vascularity of tumors measured by HF and LF SHI. The 
measures of vascularity, that will be obtained from ultrasound images and pathological 
tumor specimens stained for respective markers will be compared using linear correlation 
to find out which ultrasound technique is more significant determinant of tumor 
vascularity for all the respective markers. We hypothesized that; both the ultrasound 
methods (HF SHI and LF SHI) would provide significant results for fractional vascularity 
comparisons for at least one of the three immunohistochemical markers.  
 
6 
 
2. BACKGROUND AND LITERATURE REVIEW	  
	  
	  
	  
 This chapter presents background information and review of literature pertaining 
to breast cancer and its diagnosis, tumor angiogenesis, ultrasound as a diagnostic imaging 
modality for breast cancer and the use of contrast agents and subharmonic ultrasound 
imaging technique and a current review of high frequency subharmonic ultrasound 
imaging technique. 	  
	  
2.1 Breast cancer and diagnosis 	  
Cancer is formed by uncontrolled change in cell differentiation. They often lead 
to metastasis of the transformed cells or even death. The breast cancer originates in the 
lobules and inner lining of ducts in the breast tissue [30]. Worldwide, it is estimated that 
more than one million women are diagnosed with breast cancer every year, and more 
than 410,000 will die from the disease, representing 14% of female cancer deaths [31]. 
Breast cancer is the second leading cause of death in women exceeded only by lung 
cancer [32]. The American Cancer society estimated approximately 39,620 US women to 
die from breast cancer in the year 2013 [32].	  Besides skin cancer, breast cancer is the 
most commonly diagnosed cancer among American women. 22.9% of cancers in women 
are breast cancers [33]. On an average, each year, about 185,000 women in the United 
States are diagnosed with breast cancer and about 44,000 die from it [31].The survival 
rates for breast cancer depend highly on the type of cancer and is the stage at which it is 
diagnosed. Detection of the cancer in early stages is very crucial, since it can prevent 
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metastatic spread of the tumor. While mammography is the most widely used technique 
for screening breast cancer, it does not always differentiate between benign and 
malignant masses and hence has to be supplemented by biopsies. . Hence in 2002, Taylor 
et al. conducted a study with 761 breast masses to determine if complementary US 
imaging and Doppler could decrease the number of biopsies for benign masses and 
showed that ultrasound can be used as an adjunct technique when mammographic 
findings are indeterminate for the decision of biopsy or follow-up [34]. Besides having 
the potential for improving characterization of breast lesions - benign and malignant, 
ultrasound also reduces patients need to undergo breast biopsy and eliminates the risk of 
getting exposed to ionizing radiations.   
	  
2.2 Tumor angiogenesis 	  
 Angiogenesis is an essential physiological phenomenon of formation of new 
blood vessels from already existing ones. It is an essential physiological step in 
reproduction, wound repair and tissue response to ischemia [1]. Pathological 
angiogenesis (neovascularization) has been proved as an important factor in proliferation 
and expansion of tumor and metastasis [2]. 	  
Judah Folkman was the first to propose the role of angiogenesis in tumor growth where 
he laid the hypothesis that neovasculature is needed to support the growth and metastasis 
of tumors, and hence anti-angiogenic treatment might be an effective way to cure cancer 
[6]. While the tumor is in avascular stage (tumor mass<0.5 mm3), its cells receive 
sufficient nutrition and oxygen through diffusion. Its growth is limited during this stage 
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[2]. Tumor remains in dormant state (cease growing) until it can stimulate additional 
blood vessel growth by means of angiogenesis [2].  For further growth,  more nutrition, 
oxygen and removal of waste products is essential for the parenchymal cells, which takes 
place by development of additional vascular network around the tumor. At this time 
tumor enters the vascular stage. In this stage, new capillaries invade the tumor and allow 
it to spread to the circulatory system; proceeding towards metastasis [2].  The process of 
angiogenesis is complex and consists of changes in balance between angiogenic and 
antiangiogenic factors, change in morphology of endothelial cells, release of proteolytic 
enzymes, migration of endothelial cells and capillary morphogenesis, reproduction of 
endothelial cells and microvascular differentiation [2]. This process is tightly regulated 
by several stimulatory and inhibitory factors and proceeds only when angiogenic factors 
that promote new vessel growth are predominant [3]. Owing to the fundamental role that 
angiogenesis plays in cancer growth and metastasis, there has been a growing interest in 
research related to its regulatory mechanism and clinical implications in the past three 
decades [4].  	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Figure 2.1: A figure representing basic steps involved in tumor angiogenesis. Here stage A represents the 
tumor in its avascular stage where it obtains its nutrients and blood supply from the host endothelial cell. 
Stage B represents release of angiogenic factors as the tumor starts growing beyond 1mm in size which 
stimulates migration, proliferation and formation of neovessels by endothelial cells in adjacent vessels. 
Stage C represents a newly vascularized tumor which progresses towards metastasis. Reproduced from 
[37].  
 
 
 
2.2.1 Factors regulating angiogenesis 	  
 There has been a plenty of research since 1970’s to characterize different 
angiogenic mediators. These regulating factors are secreted by the tumor cells in the 
angiogenic phase, as a response to certain stimulus to signal the need for blood supply. 
Most of the angiogenic factors are directly concerned with endothelial cell proliferation 
[2]. The most potent regulators of angiogenesis which were selected for this study are 
vascular endothelial growth factor (VEGF), platelet endothelial cell adhesion molecule 
(PECAM or CD31) and cyclooxygenase-2 (COX-2). 
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2.2.1.1 Vascular Endothelial growth factor 	  
 Vascular endothelial growth factor (VEGF) is a cell signaling protein which plays 
an important role in the growth and differentiation of vascular as well as lymphatic 
endothelial cells. Expression of VEGF by tumor cells stimulates angiogenesis and 
enables them to grow and undergo metastasis thus, making VEGF an important factor in 
new vessel formation throughout the tumor development. The blood vessels formed by 
VEGF expression and without smooth muscle coating are often immature, tortuous and 
leaky unlike normal blood vessels [3]. VEGF induced tumor vasculature has a number of 
structural and functional abnormalities including increased permeability and chaotic 
structure. These abnormalities promote tumor growth [3]. Besides this, the expression of 
VEGF also promotes survival of new vasculature by preventing the new endothelial cells 
from undergoing apoptosis [3].  
	  
2.2.1.2 Platelet endothelial cell adhesion molecule (PECAM -1 or CD 31)	  
 Platelet endothelial cell adhesion molecule (PECAM-1) also known as cluster of 
differentiation 31 (CD31) is another signaling protein found on the surface of monocytes, 
T-cells which form the intercellular junctions of endothelial cells [35]. Formation of new 
blood vessels depends on disruption of cell-cell attachments of endothelial cells, their 
migration and forming new attachments to promote blood flow. The PECAM-1 
molecules located at the endothelial cell junctions initiate the formation of new junctions 
[10]. Findings by DeLisser et al. in rat and murine models of angiogenesis further suggest 
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that interactions of cell-cell adhesion molecules are important in formation of new blood 
vessels and hence angiogenesis [10]. 	  
2.2.1.3 Cyclooxygenase-2 (COX-2)	  
. Cyclooxygenase-2 also known as Prostaglandin-endoperoxide synthase 2 is an 
isoform of COX which is responsible for formation of prostaglandins. The enzyme COX-
2 is not normally present in cells, but is induced by pain and inflammation by 
intracellular messengers. COX-2 expression occurs in a wide range of preneoplastic and 
malignant conditions; it is localized to the neoplastic cells, endothelial cells, immune 
cells, and stromal fibroblasts within tumors [36]. It is expressed in 40% of colorectal 
adenomas and many other types of carcinomas [2]. The studies conducted by Denkert et 
al. indicate that COX-2 is expressed in human malignant melanoma and is also involved 
in regulation of the melanoma invasion [37]. This molecule may also be implicated in 
several mechanisms of tumor expansion, and metastatic potential such as tumor 
proliferation, apoptosis and angiogenesis [11].  
	  
	  
2.3 Ultrasound contrast agents 	  
 Ultrasound contrast agents constitute of high molecular weight gas-filled 
microbubbles typically 1-10 μm in diameter and stabilized by a thin (nm) outer shell of 
lipid, protein or fatty acid. Their smaller diameters enable them to mimic the red blood 
cells and easily enter the capillary network [38]. Table 2.1 below shows current 
ultrasound contrast agents commercially available at one time. These agents can be 
injected intravenously (as they are transpulmonary) to improve the contrast of ultrasound 
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imaging by 15-25 dB and hence, increase the sensitivity of ultrasound imaging [15-17]. 
This increase in sensitivity is due to impedance mismatch between blood and air/gas 
filled inside the microbubble.  Gramiak and Shah were the first to use contrast agents in 
1968 and prove that the gas in these bubbles led to increased reflectivity in blood or 
tissue [39]. 	  
  
 
 
Table 2.1:  Commercially available UCAs. Reproduced from [69]. 
Name Manufacturer Year Gas Coating Availability 
Echovist Bayer Shering 
Pharma AG 
1991 Air Galactose Off market 
Albunex Molecular 
Biosystems 
1994 Air Human Albumin Off market 
Levovist Bayer Shering 
Pharma AG 
1996 Air Galactose Off market 
Optison GE Healthcare 
AS 
1997 C3F8 Human Albumin EU, USA 
Definity Lantheus 
Medical 
Imaging 
2001 C3F8 Phospholipids Worldwide 
SonoVue Bracco SpA 2001 SF6 Phospholipids Europe, S 
Korea 
China, India, 
Hong Kong, 
Singapore 
Imagent Alliance 
Pharmaceutical 
Corp. 
2002 C6F14 Phospholipids Off market 
Sonazoid Amersham 
Health 
2006 C4F10 Phospholipids Japan 
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When a microbubble is insonified by an ultrasound wave it undergoes alternate 
phases of compression and expansion. The size of the microbubble reduces in the positive 
half cycle and it expands in the negative half cycle of the ultrasound pressure wave. This 
behavior of the microbubbles is dependent on the frequency of the incident ultrasound 
wave and acoustic pressure amplitude [40]. However, for higher acoustic pressure 
amplitudes, the extent to which the bubbles are compressed during the positive pressure 
phase does not correspond to the extent of expansion in the negative pressure phase, 
which results in asymmetrical and nonlinear bubble oscillations [41]. 	  
	  
	  
	  
	  
Figure 2.2: A figure representing the acoustic nonlinear response of contrast agent microbubbles. At higher 
pressure incident RF acoustic fields the microbubbles do not compress in the positive pressure phase as 
much as they expand in negative phase thus generating a nonlinear response. As a result of this 
asymmetrical contraction and expansion the bubbles produce harmonics in the received echoes of the 
ultrasound beam. Reproduced from [68]. 
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2.4 Nonlinear imaging with Ultrasound contrast agents 	  
Microbubbles detection within the neovessels requires an increased sensitivity to 
specific microbubbles acoustic signatures and reduced sensitivity to echoes from the 
surrounding tissue [18]. The nonlinear behavior of ultrasound contrast agents can be 
utilized to enhance the contrast relative to surrounding tissue using the imaging methods 
described below.	  
	  
	  
2.4.1 Harmonic Imaging 	  
The backscattered signal from the microbubbles contains second and higher 
multiples of the fundamental frequency. The technique of harmonic imaging uses these 
frequency components for ultrasound imaging which increase the contrast between the 
bubbles and the tissue. Conventional harmonic imaging (HI) was the first non-linear 
contrast enhanced US imaging technique developed, wherein, the ultrasound beam is 
transmitted at a fundamental frequency fo and the displayed image is reconstructed from 
the second harmonic component 2fo. The received echoes consist of a spectral overlap 
between fundamental and received second harmonic signals and hence they are filtered to 
minimize this overlap. [18]. Hence this method uses narrower bandwidth for imaging in 
order to make sure that the received signal can be separated from the fundamental signal. 
If the bandwidth of the received and the fundamental signal components overlap, they 
cannot be completely separated in the receive process. The narrowband transmitted pulse 
used in HI reduces both spatial and contrast resolution [18]. Another disadvantage in 
harmonic imaging is that the tissue also produces sufficient harmonic energy to be 
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detected by the high sensitivity and bandwidth of modern ultrasound equipment. Thus, a 
tissue image would always be present, even in the absence of contrast agents [18]. 
Furthermore, the higher attenuation of the harmonic frequencies compared with the 
fundamental frequency reduces imaging depth somewhat [19]. 
	  
2.4.2 Pulse inversion Imaging 	  
 Pulse inversion was proposed by Patrick Phillips. This technique uses two RF 
pulses, which are fired consecutively. The second pulse transmitted is inverted in phase 
with respect to the first pulse. In any linear system the response of second pulse is an 
inverted copy of the response from first pulse and hence the sum of two responses is zero 
while in any nonlinear system (such as gas microbubbles) the responses will not be 
inverted copies and will end up in a non-zero sum. The remainder is related to the degree 
of nonlinearity [23]. Besides this, the signal amplitude doubles in the summation process 
and even the noise level reduces providing a higher signal to noise ratio [23]. This 
technique has also shown an improvement of 14 dB in contrast tissue ratio over 
fundamental imaging at a transmit frequency of 2MHz [42]. 
 
2.4.3 Amplitude Modulation 	  
This technique sends two consecutive ultrasound pulses into the tissue, where the 
first pulse is scaled by a factor relative to the second pulse [42, 43]. The signals are 
received after scaling the response of the second pulse by the same factor. Subsequent 
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subtraction of successive echo signals yields cancellation of linear tissue signals and 
retains the nonlinear UCA echo signals. It was demonstrated that this technique could 
produce a contrast to tissue ratio of 14dB and higher at 2 MHz [42]. However there are 
no reports yet on the use of AM at higher transmit frequencies (>2MHz).  
	  
2.4.4 Subharmonic imaging 	  
 Harmonic imaging is limited at high frequencies because significant harmonic 
signal is also generated in tissues at diagnostic pressures, which degrade the contrast to 
tissue ratio. Hence subharmonic imaging was introduced, which was able to achieve high 
agent-to-tissue contrast at acoustic pressures and frequencies currently used in diagnostic 
ultrasound [19]. Subharmonic imaging involves receiving the transmitted echoes of 
ultrasound wave at half of the transmit frequency (fo/2). 	  
 According to Eller and Flynn, a free gas microbubbles is able to emit 
subharmonics only when the exciting acoustic signal exceeds a certain threshold pressure 
which is calculated by the following equation: 	  
	  
𝜌   !! =   𝜌 𝐴 ×     !! [   !!! !   − 4]!   +   (!!! )!                                       Eq1	  
 
Where𝜔, 𝜔0  λ and are the angular driving frequency, angular bubble resonance and the 
logarithmic decrement respectively and 𝜌 𝐴   is the incident sinusoidal pressure field [26].	  
17 
 
This pressure is minimal at twice the resonance frequency of gas bubble and 
depends on the elasticity and viscosity of the microbubbles [44]. Besides this, more 
dominant subharmonic peaks are obtained if the signals are narrowband [40]. The in vitro 
experimental studies carried out by Shankar et al in 1998 suggested that the ratio of sub-
harmonic backscattered from contrast to that backscattered from tissue, is stronger than 
the ratio of backscattered second harmonic [19]. As a result, blood that contains contrast 
should be more easily detectable with respect to tissue if the sub-harmonic, rather than 
the second harmonic, is used for imaging. In 2007, Forsberg et al were the first to 
conduct subharmonic imaging studies on humans and showed that the in vivo SHI images 
from human breast cancer lesions improved the diagnosis of breast cancer (81% 
accuracy) and a trend toward significant improvement over mammography (p=0.07) 
unlike other methods conventional US, power Doppler ultrasound [22].  	  
 Goertz et al. compared the contrast tissue ratios for intravascular images obtained 
from high frequency subharmonic imaging (Tx: 40 MHz/Rx: 20 MHz) with those from 
standard harmonic imaging (Tx: 20 MHz/Rx: 40 MHz) using pulse inversion. The later 
showed an enhancement up to 10-20 dB over subharmonic imaging (with contrast tissue 
ratio ranging from 5-15 dB) [25]. They showed that at high frequencies particularly for 
second harmonic imaging the contrast tissue ratio decreases as the imaging depth and 
transmit pressure are increased. A better contrast to tissue ratio would enable better 
visualization of tumor neovessels and considering tumor neovascularity as a predictor in 
characterizing breast lesions, subharmonic contrast enhanced ultrasound could also be 
used for diagnosis of breast cancer; but at frequencies <40 MHz. 	  
18 
 
2.4.3.1 High frequency subharmonic imaging 	  
 Performing ultrasound imaging at high frequencies, increases image resolution at 
the expense of image penetration depth. It is currently widely used in pre-clinical imaging 
of small animals where high spatial resolution is needed. Typical frequencies range from 
20–70 MHz (resulting in axial spatial resolution of 20–80 µm) compared with 
frequencies commonly used for clinical purposes in the range of 1–15 MHz (with an axial 
spatial resolution of 100–1500 µm) [45]. Thus micro-ultrasound used at higher 
frequencies (>20 MHz) significantly improves the resolution of received signals [28]. 
Developments in linear array technologies for transducers have enabled imaging at 
frequencies in the range of 15-70 MHz [46]. Ultrasound systems operating at high 
frequencies not only depicted small anatomical structures [47], but were even able to 
image functional blood flow of microvasculature [29]. Recently, there have been many 
studies assessing the efficacy of high frequencies for imaging small animals.. 	  
 Goertz et al. in 2005 were the first to use the nonlinear harmonic signals 
transmitted at high frequencies (>20 MHz) from microbubbles to differentiate between 
microbubbles and tissue signals [24]. They further extended their results in use of 
nonlinear imaging (pulse inversion) of targeted microbubbles with intravascular 
ultrasound [25]. In 2009, the in vitro experimental studies conducted by Needles et al. 
proposed a method of using high frequency subharmonic imaging to separate bound 
targeted microbubbles signals from free bubble signals and tissue [26]. The ultrasound 
systems used for all the above studies used single-element mechanically scanned 
transducers which limited contrast enhanced imaging of small animals and also provided 
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poorer depth of field leading to poor detection of ultrasound contrast agent [27].  A larger 
depth of field is necessary for better contrast detection, which not only improves the 
overall image quality but also the consistency of microbubble contrast images [27]. The 
recent study conducted by Needles et al in 2010 used an array based micro ultrasound 
system operated in the range of 18- 24 MHz for assessing the contrast to tissue ratios 
obtained from nonlinear  fundamental and subharmonic signals in murine kidneys [27]. 
The largest improvements observed in contrast tissue ratios were for 18 MHz with 
AM/PIAM and fundamental bandpass filter (13 dB) and for 24 MHz with PI and 
subharmonic bandpass filter (15 dB). 	  
This thesis work intends to use a similar micro-ultrasound system at a frequency 
of 24 MHz to depict the tumor microvasculature in murine breast cancer models and 
obtain and compare the vascularity measures from these images with the ones obtained 
from a low frequency ultrasound system. 	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3. MATERIALS AND METHODS	  
	  
	  
	  
3.1 Materials	  
3.1.1 Cells and culture material	  
 Human breast adenocarcinoma cells (MDA-MB-231) were purchased from ATTC 
(Manassas, VA). This cell line shows epithelial-like morphology and has an invasive 
phenotype in-vitro. In vivo these cells are capable of forming tumors in mammary fat 
pads of nude rats by intravenous injections.	  
RPMI-1640 medium (containing 2 mM L-glutamine, 10 mM HEPES, 1 mM 
sodium pyruvate, 4500 mg/L glucose, and 1500 mg/L sodium bicarbonate) were 
purchased from ATCC (Manassas, VA).Penicillin/streptomycin antibiotic was purchased 
from Sigma Chemical Co., St. Louis, MO. Dulbecco’s Modification of Eagle’s Medium 
(DMEM) (1X containing 4500mg/L glucose without L-glutamine) was purchased from 
Mediatech Inc. (Manassas, VA). Trypsin EDTA, fetal bovine serum (FBS), Phosphate 
buffered saline (PBS) and isopropyl alcohol were all reagent grades and purchased from 
Fisher Scientific (Springfield, NJ).	  
	  
 	  
3.1.2 Contrast Agent	  
 The contrast agent Definity® (Lantheus Medical Imaging, N Billerica, MA) was 
used for all the imaging studies. Definity® vial (Perflutren Lipid Microsphere) for 
injectable suspension consists of lipid-coated microspheres filled with octafluoropropane 
(C3F8) gas. The microspheres contained in Definity® have a mean diameter of 1.1 – 3.3 
µm (in vitro measurements) with 98% of the particle population being less than 10 µm in  
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diameter and a maximum diameter of 20 µm. Definity® is supplied as a single use 2-mL 
clear glass vial containing clear liquid. Prior to its usage, it is allowed to warm at room 
temperature and then activated by shaking the vial for 45seconds using Vialmix®. After 
activation, 1 mL of Definity® contains approximately 1.2x1010 Perflutren lipid 
microspheres [48].  
	  
3.1.3 Imaging equipment 	  
 Two ultrasound scanners, a modified Sonix RP (Ultrasonix, Richmond, BC, 
Canada) and Vevo 2100 (Visual Sonics, Toronto, ON, Canada) were used for low 
frequency and high frequency ultrasound imaging respectively. 	  
The Sonix RP scanner provided full access and control of radio frequency (RF) 
imaging data as well as enabled configuration of new modes like pulse inversion. A L9-4 
linear array transmitting at 8 MHz was used in conjunction with this scanner [49]. 	  
The Vevo 2100, a micro ultrasound scanner enabled imaging at high frequencies 
[50]. A MS 250 linear array transducer that provided 30 µm image resolutions through 
the entire field of view and transmitting at 24 MHz was used for obtaining high 
frequency scans [50]. 	  
A semi-automated histomorphometry system based on a DXC-970 MD color 
CCD camera (Sony Corporation, Tokyo, Japan) connected to a SMZ-10A microscope 
(Nikon, Melville, NJ, USA) was used to analyze the pathological tumor specimens using 
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a motorized stage, controlled by ImagePro Plus software (Media Cybernetics, Silver 
Spring, MD, USA).   
	  
3.2 Methods 	  
3.2.1 Cell culturing and injections 
The MDA-MB-231 cells were initially thawed to get them to room temperature 
and then cultured in a medium at 37°C in 5% CO2. The cells were monitored on a daily 
basis to keep a check on the medium, the confluence level of the cells, whether they are 
alive and not contaminated. After they reached 80-85% of confluence, they were sub 
cultured using 0.25% trypsin (to detach cells adhered to the walls of petri dishes) and 
growth medium (to stop the enzymatic action of trypsin) and then split into even volumes 
and incubated at 37°C in 5% CO2 until they reach a confluence of 75-80% . The sub 
culturing was repeated until the number of cells was in order of 106. The detailed 
procedure for cell culturing is provided in Appendix 1.   
After culturing, 5 × 106 cells were mixed with matrigel, which helps in forming 
human tumor xenografts in nude rats. They were injected subcutaneously in right 
mammary fat pads of 19 athymic immunodeficient rats. 	  
The growth of the tumors was monitored and measured by means of vernier 
calipers over 3 weeks. Based on the progression of tumor growth, the rats were 
categorized for scanning studies, conducted after 21, 24 and 28 days of cell injections. 
The first 8 tumors that grew beyond 5×5×5 mm3 in size were selected for the 21st day of 
scanning, while the remaining were allowed to grow. On the 23rd day the tumor growth 
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was again monitored and the 4 tumors that grew more than 5×5×5 mm3 were selected for 
24th day of scanning experiments. Amongst the remaining 7, only the 4 rats that 
developed tumors were scanned on the 28th day. The remaining three rats that did not 
show any tumor growth were euthanized. Sixteen out of nineteen rats showed a marked 
tumor growth with their diameters ranging from 5-13 mm. After the ultrasound scans 
were obtained, the animals were euthanized by placing them in a gas chamber and 
saturating the air with CO2. The tumors were surgically removed and scanned to identify 
the imaging plane that was studied in vivo. All the animal studies were carried out 
ethically under the supervision of a veterinarian and were approved by the Institutional 
Animal Care and Use Committee of Thomas Jefferson University.	  
	  
3.2.2 Acquisition of Ultrasound data	  
For the imaging studies, rats were intubated and anesthetized with 0.5 to 2 % 
Isoflurane (Iso-thesia; Abbott Laboratories, Chicago, IL). Also a warming blanket was 
used to maintain normal body temperature. They were placed in supine position on the 
operating table. 	  
For imaging method there were 7 intravenous injections in the tail vein of the rats. 
A saline flush of 0.2cc was given after every injection. For low frequency studies, 
baseline imaging was done to adjust the output power for optimized pressure 
measurements and then keep the power constant throughout the studies. This was 
followed by depth, width and height measurement of the tumor. Transducer was placed 
so as to image the largest cross-sectional area throughout the studies. Definity was 
injected (dose: 36µl) via the lateral tail vein of the rats using a 24 gauge needle. Three 
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contrast injections were administered followed by image acquisition in the right 
mammary pad of each rat (i.e., over the tumor) with an interval of 3-4 min between the 
injections, so that the agent had enough time to clear the blood pool. The images were 
then acquired at the optimal power setting. The final three injections were for scanning 
the normal tissue (left thigh), which would act as a reference standard and show if there 
was a clear demarcation between the tumor and normal tissue. High and low frequency 
scans were done using the respective scanners, as described below. 	  
	  
3.2.2.1 Low frequency SHI 	  
A Sonix RP scanner (Ultrasonix Medical Corp., Richmond, BC, Canada) using a 
L9-4 linear array transducer (bandwidth: 9-4 MHz) was operated in the Research mode, 
which  enables control of imaging parameters and apply various post-processing and 
display methods in real-time on RF, I/Q and envelope data to output and store the 
ultrasound information[50] . The transmit frequency for the transducer was 8 MHz while 
the echoes were received at 4 MHz (subharmonic frequency). All the parameters used for 
acquiring the data can be seen in Table 3.1. The Sonix RP scanner was configured to 
operate in pulse-inversion imaging mode. In pulse-inversion mode, 2 pulses with a 180° 
phase difference are transmitted and the received echoes are summed, cancelling the first 
harmonic and other odd linear signals and enhancing the even nonlinear signals. Thus 
pulse inversion provides an improved contrast to tissue ratio over fundamental imaging. 
Digital cine clips of LF sub harmonic images were stored for each contrast injection in 
the hard drive of the scanner.  
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Table 3.1: Image acquisition parameters in Sonix RP for LF SHI 
 
Transducer name L9-4 
Mode Pulse Inversion 
Transmit frequency 8 MHz 
Receive Frequency 4 MHz 
Power -10 dB 
Depth 3 cm 
Pulse repetition frequency 2.56 kHz 
Sampling frequency  40MHz 
Line density 128 
 
 
 
3.2.2.2 High frequency SHI	  
 A Vevo 2100 (Visual Sonics, Toronto, ON, Canada) was used to obtain high 
frequency scans. MS 250, a linear array micro scan transducer was operated in nonlinear 
contrast imaging mode transmitting and receiving at 24MHz. Table 3.2 shows the image 
acquisition parameters used for HF SHI.  In nonlinear contrast mode, the amplitude of the 
ultrasound pulses is modulated so as to utilize the nonlinear response from the 
microbubbles. Amplitude modulation (AM) sends two ultrasound pulses consecutively 
with first pulse scaled by a factor relative to second pulse and receives the signal by 
scaling in response to the second pulse by same factor [42]. It is followed by subtraction 
of successive echo signals that cancels the linear tissue echoes and retains nonlinear 
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contrast agent echo signals [42]. Thus it provides better sensitivity by maximizing the 
ratio of detected contrast agent signals to the residual tissue signals. The digital cine 
loops of high frequency images were stored in the scanner hard drive for all the 
injections.  
Table 3.2: Image acquisition parameters in Vevo 2100 for HF SHI 
 
Transducer name MS 250 
Mode Nonlinear contrast 
Transmit frequency 24 MHz 
Receive Frequency 24 MHz 
Power 4% 
Gain  35dB 
Depth 14 mm 
Width 23 mm 
Dynamic Range 35 dB 
Frame rate 21 
	  
 
 
 
3.2.2.2.1 Filter Design and Implementation 	  
The high frequency data obtained from Vevo 2100 was acquired with a transmit 
and receive frequency of 24 MHz. To optimize the RF spectrum of the data for its 
subharmonic frequency (̴12 MHz), the RF data was filtered using various digital filters. 
Digital filters were designed and tested for their ability to filter the subharmonic signal 
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component from the ultrasound contrast agent and suppress the background tissue 
signals.  	  
Individual RF A-lines were extracted from the data frame (332 A-lines with 8960 
sampling points per line) with maximum contrast mean power. A subharmonic adaptive 
algorithm as seen in Appendix 2.a was custom developed in the ultrasound research lab at 
Thomas Jefferson University, which calculated the fast Fourier transform (FFT) of the 
RF data and displayed the RF spectrum in Matlab. It was implemented to identify all the 
signal peaks in the extracted RF A-lines. Figure 3.3 shows a spectrum for one A-line with 
all the signal peaks marked. The peaks in the vicinity of the sub harmonic components 
were located from the generated RF spectrum and a band pass filter was developed 
around this location. This was repeated for all the A-lines in the frame so as to 
compensate for the variability in the RF signal. 
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 Figure 3.1: A Radio-frequency spectrum generated for one A-line showing fundamental and subharmonic 
peak.  
	  
	  
	  
Twenty bandpass were designed with 4 different orders (starting from 2; the 
lowest filter order > 0) and 5 different bandwidths estimated to be around the vicinity of 
subharmonic peak so as to retain the subharmonic component and filter the noise 
components of the signal. All the filters were assessed qualitatively for image noise and 
contrast visualization (Table 3.3). 
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Table 3.3: Classification of 20 Bandpass filters. Fs: sampling frequency. Fc1 and Fc2: cut 
off frequencies 1 and 2.	  
	  
Response 
type 
Design 
method Order 
Frequency 
Specification(MHz) Filter no. Fs Fc1 Fc2 
Bandpass IIR Butterworth 
2 
400 
8 16 BP1 
9 15 BP2 
10 14 BP3 
11 13 BP4 
11.5 12.5 BP5 
4 
8 16 BP6 
9 15 BP7 
10 14 BP8 
11 13 BP9 
11.5 12.5 BP10 
6 
8 16 BP11 
9 15 BP12 
10 14 BP13 
11 13 BP14 
11.5 12.5 BP15 
8 
8 16 BP16 
9 15 BP17 
10 14 BP18 
11 13 BP19 
11.5 12.5 BP20 
	  
 
 
 
The images selected from an entire cine loop to analyze these filters were the ones 
at the time point of maximum contrast mean power (figure 3.2). These images were 
scored by a reader on a visual analogue scale of 1 to 5 (worst to best respectively). The 
scores of the filters were averaged over each injection and were plotted for each bandpass 
filter. Figure 3.3 shows an example of scored filtered images. 	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Figure 3.2: A graph shows wash-in curve fitted to the contrast mean power within the tumor area marked 
alongside for one contrast injection in nonlinear contrast mode. It provides the data for contrast mean 
power quantified and smoothed by Vevo software at all the time points in the injection acquired from Vevo 
2100. 	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a.)                                                                   b.)  
 
c.) 
 
Figure 3.3: An example of filtered images obtained from different filters scored 1, 3 and 5 for image a.), 
b.) and c.) respectively. The score of images were higher for better contrast and the lesser the image noise  
 
 
 
A Wilcoxon signed rank test was used to compare the maximum scoring filters 
(on a per rat basis) so as to find out the filter that scored significantly as compared to the 
others.	  
The final bandpass filter selected was applied to the data corresponding to the 
analyzed RF A-line and the filtered image was then generated from that filtered RF data. 
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This was repeated for all the A-lines in each frame at all the time sequences. The 
resulting filtered images were then categorized as high frequency subharmonic images 
(HF SHI).	  
	  
3.2.3 Pathological data  	  
The tumor specimens were placed in 10 % neutral buffered formalin (Fisher 
Scientific, Houston, TX) for 12-24 hours to fix all the angiogenic markers, dehydrated in 
graded alcohols, cleaned in xylene and embedded in paraffin using standard methods. 	  
Angiogenesis consists of three stages, activation, migration and proliferation of 
endothelial cells. The three immunohistochemical markers associated with tumor growth 
are, vascular endothelial growth factor (VEGF) which promotes tumor growth, invasion 
and metastasis, cyclooxygenase-2 (COX-2) expressed in response to growth factors, 
tumor promoters and cytokines, a potent endothelial cell marker platelet endothelial cell 
adhesion molecule (PECAM or CD31) whose expression is limited to the intercellular 
junctions of endothelial cells. Each specimen was dissected with slice thickness not more 
than 4mm and stained immunohistochemically against each of these markers. A 
monoclonal antibody against PECAM (anti CD31; Dako Corporation, Carpinteria, CA), a 
polyclonal antibody against COX-2 (Santa Cruz Biotechnology, Santa Cruz, CA), and a 
monoclonal antibody against VEGF (Oncogene Research Products, San Diego, CA) were 
used for staining. Finally, the stained sections were mounted onto glass slides for further 
analysis. 	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3.2.4 Image analysis 	  
3.2.4.1 Analysis of pathological data 	  
 A semi-automated histomorphometry system based on a DXC-970MD color CCD 
camera (Sony Corporation, Tokyo, Japan) connected to a SMZ-10A microscope (Nikon, 
Melville, NJ, USA) was used to analyze the tumor specimens. The histomorphometry 
system used a 10x objective and a 10x ocular magnification (total magnification 100x) to 
provide digital images of the each histologic slide on the desktop computer. A motorized 
stage, controlled by ImagePro Plus software (Media Cybernetics, Silver Spring, MD, 
USA) was used to move the specimen until red-green-blue (RGB) images of the entire 
tumor area were obtained. The blue image which showed tissue enhancement was 
extracted from the RGB color model. Then the RGB images were converted to hue 
saturation intensity (HSI) images and the saturation image which indicated vessel 
enhancement was extracted from HSI color model. The blue image was subtracted from 
the saturation image and the total area of the tumor was obtained from this image, the 
tumor was outlined manually on the images where the tumor occupied less than 25% of 
the entire image area.  The subtracted images were enhanced using 3×3 open and sharp 
filters. The RGB channels were used to segment and count the number of colored or 
stained pixels as well as total number of pixels in the tumor. Fractional tumor vascularity 
(FV) was calculated as the number of colored pixels (ci) relative to the total number of 
pixels (ci+xi).  
                                                                                                    𝐹𝑉 =    𝑐𝑖𝑐𝑖 + 𝑥𝑖                                                                                         (1)         
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The FV measures were obtained for all the specimens stained for the each of the 
immunohistochemical marker (VEGF, CD31 and COX-2) and marker specific 
pathological maps were created for every tumor specimen using Microsoft Excel 2010. 
Considering the heterogeneous nature of tumor vasculature, based on the size of each 
tumor, it was divided into small ROIs of 3-4 mm and the fractional vascularity for each 
ROI was compared to FV obtained from respective ROIs of ultrasound images (HF SHI 
and LF SHI).  	  
	  
3.2.4.2 Analysis of ultrasound data	  
 The tortuous morphology of tumor angiogenesis was visualized in detail using 
maximum intensity projection (MIP) technique [51] .MIP technique involves selection of 
pixels in the image with maximum values, throughout a series of low power grayscale 
images as the bubbles start replenishing the image plane. An algorithm was developed in 
the ultrasound research lab of Thomas Jefferson University Hospital to obtain an MIP 
image of the input image followed by manually outlining the region of interest (ROI) on 
the MIP image, corresponding to the ROIs marked for tumor specimens. The algorithm 
calculates the FV by classifying the pixels in the image into tumor vasculature pixels and 
tumor background pixels and then calculates an optimum threshold value separating these 
two types of pixels. The algorithm then displayed the composite image showing the 
tumor vascular architecture for respective region of interest (figure 3.9). This process was 
performed on high frequency as well as low frequency subharmonic images. All the 
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algorithms and filters were developed and implemented using MATLAB (R2013a, The 
Mathworks Inc., Natick, MA). 
	  
	  
	  
 
Figure 3.4: An example of MIP image of the filtered HF image depicting vascular areas (in red) within a 
tumor (~ 7×8 mm) outlined in green. 	  
	  
	  
	  
3.2.5 Statistical analysis  
 The average scores of the bandpass filters used to filter the subharmonic signal 
from the RF signal of HF SHI were compared using a Wilcoxon’s signed non parametric 
test.	  
The data for FV was analyzed on a per ROI basis. Least squares linear regression 
was used to compare the measures of fractional tumor neovascularity obtained from high 
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and low frequency subharmonic images with the respective FV obtained from tumor 
specimens stained for the three immunohistochemical markers for every ROI in all the rat 
tumors. The correlation coefficients and statistically significant differences (with 
alpha=0.05) for ultrasound (high and low frequency) and pathological datasets were 
obtained and compared. 	  
All the statistical analysis was performed using IBM SPSS Statistics 20 (IBM 
Corporation, Endicott, NY, U.S.)	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4. RESULTS  
	  
	  
	  
 There were 5×106 MDA-MB-231 cells harvested and injected in 19 rats. Sixteen 
(84%) rats of the 19 developed tumor, while the remaining three did not show any tumor 
growth and hence were sacrificed before scanning studies. The 16 rats were scanned for 
LF SHI with 3 contrast injections in the tumor per rat using Sonix RP. However for the 
HF SHI studies just one successful injection was achieved for 5 of the 16 rats and hence 
those 5 were discarded. Thus the ultrasound and pathological comparison studies were 
carried out for the 11 rats each with 3 contrast injections in the tumor (for LF SHI and HF 
SHI). This study analyzed 33 pathological slides and 66 ultrasound images (including 
high frequency and low frequency images). 	  
	  
4.1 Results for ultrasound data 	  
 All the 11 rat tumors that were scanned had an average diameter of 8.69 ± 2.23 
mm. Figure 4.1 and 4.2 show the examples of scans for low frequency and high 
frequency ultrasound imaging, respectively of the same tumor.  
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Figure 4.1:  A scan image obtained from Sonix RP for low frequency at the subharmonic frequency 
(4MHz) showing the tumor (8×7mm) with its peripheral vascular areas marked. 	  
 
 
 
	  
Figure4.2:  High frequency scan obtained from Vevo 2100 of the same rat tumor as seen in figure 4.1 with 
marked vascular areas surrounding the tumor.  
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Both the low and high frequency images of tumor demonstrated the contrast 
wash-in within the tumor microvasculature. However, the clips obtained from high 
frequency scans had better resolution throughout the entire field of view and enabled 
better visualization of tortuous tumor morphology than the low frequency cine loops, 
which was due to the high transmit and receive frequency. 	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Figure 4.3: HF image frames depicting the wash-in of the contrast agent injection in nonlinear contrast 
mode of Vevo 2100 with a B-mode image on the left and contrast image on the right at a.) 2.5seconds, b.) 4 
seconds, c.) 6 seconds and d,) 8 seconds. The tumor area is marked in the B-mode images in a rectangular 
selection while the contrast images on the right show the arrows marking the contrast enhancement within 
the tumor as the time of acquisition increases beyond 2.5 seconds.	  
	  
 
 
Figure 4.3 shows the wash-in of contrast agent into the micro vessels of tumor 
scanned after 28 days of cell injections, in high frequency with Vevo 2100 at different 
time points. An inflow of contrast microbubbles is seen in the tumor as well as 
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surrounding vessels within few seconds of contrast injection, depicting intense vascular 
and less vascular areas within the same tumor and demonstrating the heterogeneous 
nature of tumor angiogenesis. These images were constructed from RF signal with same 
receive and transmit frequency (24MHz), hence to extract the subharmonic frequency 
component from the RF spectrum, the data corresponding to it had to be optimized for 
subharmonic frequency ( ̴ 12MHz) to generate respective subharmonic images. 	  
The spectral analysis for high frequency RF data (Figure 3.3) showed a dominant 
peak around 24 MHz for the transmit frequency and a significant peak at half of this 
frequency 12 MHz depicting the subharmonic signals from the contrast microbubbles.  
	  
	  
	  
 
Figure 4.4: A graph comparing the mean scores for 20 bandpass filters with scores of three maximum 
scoring filters marked in red arrows 
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Figure 4.5: A box plot of the mean scores for 20 bandpass filters 
 
 
 
 
Figure 4.4 shows a graph for the score comparison of all the 20 bandpass filters 
used to filter the subharmonic component from this RF spectrum. Three filters with mean 
scores BP4: 2.9±0.7, BP9: 3.4±0.8 and BP14: 2.9±0.7 were analyzed further. A 
Wilcoxon’s signed rank test was performed to compare the mean scores per rat of these 
three bandpass filters. No significant difference was found between scores of BP4 and BP 
14 (p=1.0). The filter BP9’s scores were significantly higher when compared to those of 
BP4 (p=0.005) and BP14 (p=0.003). Table 4.1 shows the mean score comparison of all 
the filters. The filter BP9 showed less image noise and provided better contrast 
visualization as compared to other filters and hence was selected for filtering the 
subharmonic component from the high frequency image scans in order to create the final 
SHI images. Table 4.2 provides the frequency specifications for BP9.  
43 
 
Table 4.1: Mean scores and standard deviations of the 20 bandpass filters	  
Filter no.	   Mean scores	   Standard 
Deviation	  
BP1	   2.0	   0.3	  
BP2	   2.0	   0.1	  
BP3	   2.3	   0.6	  
BP4	   2.9	   0.7	  
BP5	   1.3	   0.7	  
BP6	   2.0	   0.1	  
BP7	   2.0	   0.2	  
BP8	   2.7	   0.4	  
BP9	   3.4	   0.8	  
BP10	   1.0	   0.0	  
BP11	   2.0	   0.2	  
BP12	   2.0	   0.1	  
BP13	   2.7	   0.6	  
BP14	   2.9	   0.7	  
BP15	   1.0	   0.0	  
BP16	   1.9	   0.2	  
BP17	   1.9	   0.1	  
BP18	   2.2	   0.4	  
BP19	   2.6	   0.5	  
BP20	   1.0	   0.0	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Table 4.2: Design specifications of the bandpass filter BP9 implemented and selected as 
optimal filter to extract the subharmonic frequency component from the RF spectrum 
generated by high frequency ultrasound image RF data.	  
	  
Design method	   IIR Butterworth	  
Response type	   Bandpass	  
Filter order (N)	   4	  
Sampling frequency (Fs)	   400MHz	  
First cut off frequency 
(Fc1)	  
11MHz	  
Second cut off 
frequency(Fc2)	  
13 MHz	  
Attenuation at cut off 
frequencies	  
-3dB	  
	  
 
 
 
4.2 Pathological data 	  
 The corresponding immunohistochemical stains for tumor specimens can be seen 
in Figure 4.6. Marked staining is seen for areas stained for VEGF and COX-2 in figure 
4.6 a and figure 4.6 b. However a diffused staining is seen in case of CD31 expression. 
Owing to the heterogeneous nature of tumor angiogenesis, the fractional vascularity 
measures differed significantly within different areas of the same tumor. Hence the tumor 
neovascularity was decided to be compared on a per ROI basis. Table 4.3 shows a 
pathological map of the fractional tumor vascularity in corresponding tumor areas 
obtained from a tumor specimen stained for CD31 
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Figure 4.6:  Immunohistochemical staining of an area of tumor from Figure 3.1 for (a.)VEGF, (b.) CD31 
and (c.) COX-2. 
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Table 4.3: A tumor specimen was stained for the marker CD31 and mathematical 
morphometry was performed on the RGB images of the slides using ImagePro software 
to obtain the fractional vascularity. FV for each tumor area was reported in the 
pathological map created in Microsoft Excel. Cells marked in yellow, Green and Blue 
mark the different ROIs in the map. 
 
 0.017 0.024 0.019 0.012 
 0.034 0.043 0.030 0.011 
 0.033 0.031 0.046 0.035 
0.046 0.042 0.039 0.019 0.024 
 0.047 0.021 0.015  
0.042 0.051 0.033 0.035 0.026 
 0.066 0.025 0.015 0.027 
  0.122 0.122 0.18 
  0.115 0.064  
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Figure 4.7: An ultrasound image from HF SHI marked with the ROI, encircled in green dotted line and the 
vascular areas within the ROI marked in red corresponding to the blue region marked in Table 4.3.  
	  
	  
4.3 Comparisons of ultrasound and pathological data	  
The average fractional vascularity for 11 rats was higher (p<0.05) for low 
frequency subharmonic imaging (0.38±0.05) as compared to high frequency subharmonic 
imaging (0.05±0.017). As the frequency of ultrasound increases the signals undergo more 
attenuation due to which the depth of imaging is limited [47]. Hence LF SHI was able to 
generate stronger signals which could image the tumor up to 3cm deep and depict more 
vascular areas, while HF SHI’s imaging depth was limited to 1.4cm.    However these 
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results were not yet correlated with the FV measures obtained from 
immunohistochemical stains.  
Table 4.4 shows the correlation r values and significant p values for each of the 
comparisons. Linear regression analysis performed on a per ROI basis showed the 
strongest and significant correlation between tumor vascularity depicted with HF SHI and 
the percent area stained with VEGF (r = 0.38; p=0.034). The regression analysis also 
showed a trend towards significance for comparison between HF SHI and CD31 staining 
(r=0.32; p=0.075) as well as for comparison between LF SHI and COX-2 staining 
(r=0.31; p=0.08). There was no statistically significant correlation obtained between HF 
SHI and COX-2 (r=0.018; p=0.08) and for comparisons between LFSHI and VEGF, LF 
SHI and CD31 (p>0.30). Figure 4.7 shows the scatter plots of FV measures for the 
ultrasound imaging technique corresponding to the FV measures for respective 
immunohistochemical markers. Table 4.5 shows comparison the r values and significant 
p values for comparisons of FVs obtained from HF SHI and FVs of specimens stained for 
3 immunohistochemical markers. The only significant values were obtained for 
expression of VEGF in 21 day rats (r=0.77; p=0.02) and expression of CD31 (r=0.61; 
p=0.04) in 24 day rats. There were no significant results obtained when the expression of 
these markers was compared using LF SHI at 3 different time points. 
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Table 4.4: Comparison results (r values and p values) of linear regression of FVs 
between ultrasound imaging technique (LF SHI and HF SHI) and three 
immunohistochemical markers (VEGF, CD31, COX-2).   
	  
	   	  
	  
	  
	  
	  
	  
 
 
                                         a.) 
 
	  
b.)                  c.) 
 
	  
Figure 4.7:  a.) Plot of FVs obtained from HF SHI and specimens stained for VEGF against that showed 
highest significant correlation and b.) and c.) Plots of FV from LF SHI and HF SHI against specimen 
percent area stained for COX-2 and CD 31 respectively. Note that, these plots did not show any significant 
correlation but showed a trend towards significance. 	  
    VEGF  CD31  COX-2
 LF SHI
 (n=31) 
r 0.04 0.18 0.31 
p 0.802 0.316 0.080 
 HF SHI
 (n=31)
r 0.38 0.32 0.14 
p 0.034 0.075 0.464 
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Table 4.5: Comparison results (r values and p values) of linear regression of FVs 
between HF SHI and three immunohistochemical markers (VEGF, CD31, COX-2) for 2, 
24 and 28 day rats.   
  VEGF  CD 31 COX-2  
HF SHI r p r p r P 
21 days (n=9) 0.77 0.02 0.34 0.39 0.44 0.26 
24 days (n=11) 0.15 0.67 0.61 0.04 0.22 0.51 
28 days (n=11) 0.56 0.09 0.22 0.49 0.38 0.22 
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5. DISCUSSION	  
	  
The subharmonic ultrasound images obtained using high frequency ultrasound not 
only showed better resolution and less image noise, but also depicted improved tumor 
vasculature as compared to the low frequency images. The only significant correlation 
found for the measures of FV in our studies was between HF SHI and 
immunohistochemical staining for the angiogenic marker VEGF (r = 0.38; p=0.034; 
Table 4.5). There was also a trend towards correlation seen in the results obtained for 
comparisons of HF SHI vs. CD31 and of LF SHI vs. COX-2 (r~0.31; 0.07<p<0.09; Table 
4.5). Thus contrast enhanced subharmonic imaging using high frequency ultrasound 
appears to provide a non-invasive marker for angiogenesis: particularly for the expression 
of VEGF.  
Earlier studies involving the use of contrast enhanced high frequency 
subharmonic ultrasound were based on assessing the blood perfusion parameters in small 
animal models. The study conducted by Goertz et al., showed the subharmonic 
component of a 20 MHz ultrasound pulse feasible enough to detect the micro vessels in a 
rabbit ear and mouse heart by differentiating between microbubble and tissue signals 
[24]. Recent studies conducted by Needles et al using subharmonics of high frequency 
(>20 MHz) ultrasound pulses to separate bound and free microbubbles from tissue as 
well as to assess the vascular perfusion in a mouse model using nonlinear contrast 
imaging techniques showed an improved specificity of microbubble detection [26]. 
Further studies involving high frequency used nonlinear contrast imaging techniques 
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(pulse inversion and amplitude modulation) to assess the blood perfusion kinetics in 
murine kidneys, which provided valuable parameters that help in diagnosing the 
progression of human disease models [27]. Kodama et al. proposed a method of mapping 
micro vessels with acoustic liposomes and used high frequency ultrasound to assess 
angiogenesis and evaluate antitumor effects [52].  
 There has been a plenty of research done and studies conducted in vitro as well as 
in vivo to assess the tumor vascularization; in particular the process of angiogenesis.  
Early studies by Schroeder et al assessed the degree of vascularization in 37 malignant 
melanomas of mice and found an improved correlation between percentage of vessel area 
and histologically obtained tumor vascularization (p<0.05), but there was no significant 
correlation between sonographically (using Power Doppler) and histologically obtained 
grades of tumor vascularization [53]. Iordanescu et al. derived vascularity from contrast 
enhanced Color Doppler ultrasound images and histological specimens of prostate tumor 
in 35 genetically engineered mice. The animal models used in this study were genetically 
altered by linking the prostate-specific rat probasin promoter to the SV40 large T antigen; 
these models closely mimicked the human prostate cancer progression. [54]. However, 
they did not obtain any correlations in their results. On the other hand, the set of results 
obtained by Denis et al. in their experiments on mammary tumor models of 13 rats 
showed feasibility of Power Doppler sonography in quantitation of tumor angiogenesis. 
They used the measurement parameters, color pixel density (CPD) and vascularity index 
(VI). However there were no predictive values obtained for CPD and VI for sensitivity of 
the tumors to anticancer treatment [55]. Krix et al. achieved significant 
correlation(p<0.01) between Power Doppler US and histological stains for CD31 marker, 
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using perfusion parameters such as blood volume, flow and mean velocity in 13 murine 
tumors [56]. Using a small sample size of 14 mice, significant correlations (p<0.01) were 
achieved between tumor specimens stained for COX-2 and the vascularity measures 
obtained from contrast enhanced Power Doppler imaging using human melanoma 
xenograft tumor models by Forsberg et al. [57]. This study was further extended by 
increasing the sample size to 28 mice and significant correlations between percent area 
stained with COX-2 and with VEGF relative to power Doppler and intermittent PI-HI 
(p<0.05) measures of tumor neovascularity were achieved [58].  
There were even more studies conducted to monitor angiogenesis using advanced 
ultrasound techniques such as microflow imaging, flash echo imaging, contrast pulse 
sequencing in later half of the decade that showed more positive results.  A study by Ro 
et al. showed significant correlations between vascularity measures obtained from 
contrast enhanced microflow imaging and percent area stained for COX-2 (p=0.004) and 
CD31 (p=0.043) and between flash echo imaging and area stained for COX-2 (p=0.026), 
in a murine glioma models of 21 rats [59]. Similarly, a significant correlation was 
established between microvessel density count obtained from histological stains of 
vascular markers expressed by the angiogenic endothelium and the percentage of the 
circular area enhanced by contrast pulse sequencing ultrasound technique (p  <  0.05) in a 
matrigel model of rats [60].  The contrast enhanced maximum intensity projection of 
ultrasound images showed significant results for correlation between vascularity from 
tumor specimens of NMU breast tumor model of rats stained for COX-2 and flash echo 
images [51]. Furthermore, Forsberg et al. also monitored angiogenesis in human 
melanoma xenograft models implanted in 30 mice and obtained statistically significant 
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correlations between vascularity measures obtained from histological staining for the 
marker VEGF and contrast enhanced ultrasound performed using Power Doppler and 
pulse inversion harmonic imaging techniques (p<0.01) [58]. In the light of these results, 
the correlation results obtained in this thesis project between HF SHI and tumor 
specimens stained for VEGF could also be a significant predictor of angiogenesis in rat 
tumor models. In 2010, Guibal et al. assessed the effects of anti-VEGF therapy in 32 
nude mice. This therapy was able to separate tumors that were rapidly growing from the 
ones which showed slow growth (p<0.05) by using parameters obtained from contrast 
enhanced ultrasound examinations and also showed the revascularization of tumors after 
discontinuing this therapy [61]. A similar study carried out by Ro et al. using contrast 
enhanced ultrasound monitored the effects of decoy VEGF receptor agent, which blocks 
VEGF from reaching its natural receptor. They showed positive results (p<0.04) and 
provided a conclusion that the noninvasive markers for angiogenesis are specific to the 
tumor cell lines used [62].  
The most recent studies in 2013 were conducted by Kang et al. on a rabbit 
choroidal melanoma model. They evaluated the use of high frequency contrast enhanced 
ultrasound (30 MHz) and found significant correlation (p<0.04) between the sonographic 
tumor relative blood volume and histologic tumour vascularity in terms of mean vascular 
density [63]. Horie et al.  detected early stage liver metastasis by monitoring angiogenesis 
using high frequency contrast enhanced ultrasound (40 MHz) and obtained positive 
results for correlation (p<0.05) between ultrasound and histological measures of blood 
vessels density [64]. This indicates that high frequency ultrasound could be a good 
approach for monitoring angiogenesis noninvasively and owing to the previous work 
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done for assessing angiogenesis using different ultrasound techniques, it can even act as a 
valuable marker for endothelial cells of the tumor. This thesis work has proposed the use 
of high frequency (24 MHz) subharmonic ultrasound to quantify the tumor morphology 
in rats by means of fractional vascularity which is subsequently seen as a better method 
than low frequency subharmonic ultrasound imaging in monitoring angiogenesis in rat 
tumor models. 
There are a number of limitations to this study. The number of rats (11) studied 
was very/quite small, which limits the statistical power of the study and hence the 
conclusions associated with it. Also a limited number of slides were provided for tumor 
area and vascularity assessments (3 slides per rat) hence although the entire area of tumor 
was taken into consideration for the vascularity measurements; the entire lesion 
vascularity (in 3D) was not evaluated. The elevation thickness of ultrasound beam (mm) 
is larger than the thickness of specimens by orders of magnitude (µm) due to which an 
exact match cannot be obtained between ultrasound images and tumor specimens. Few 
other limitations were; the use of pulse inversion for LF SHI studies as opposed to the use 
of amplitude modulation for HF SHI which suffers from a reduced signal to noise ratio as 
compared to pulse inversion, few of the tumors were necrotic in nature and the ultrasound 
images were also not motion compensated. The xenograft tumor model used cell lines 
which do not exactly replicate the genetics and histology of human tumors. These cells 
lack the architectural and cellular complexity of in vivo tumors, which include 
inflammatory cells, vasculature, and other stromal components [65]. However they also 
have high degree of predictability and rapidity in tumor formation which makes them 
suitable for diagnostic studies.  
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A statistical limitation arises to this study due to the multiple comparisons carried 
out. Hence a Bonferroni correction may be applied to account for the statistically 
significant results. This assigns a 0.05 p-value divided by the number of comparisons 
(here 2 imaging methods×3 immunohistochemical markers= 6) as the p value of 
significance (Bland and Altman 1995). On the other hand, there are also problems 
associated with Bonferroni correction. By controlling the group-wise error rate, each 
individual test is held at unreasonably high standard and makes it likely that legitimately 
significant results will not be detected [66]. Hence we chose not to adopt the Bonferroni 
correction for this study.  
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6. CONCLUSION AND FUTURE WORK 
 
 
 
6.1 Conclusion  
 The overall objective of this thesis was to compare High and Low frequency 
subharmonic imaging techniques with respect to their ability to depict tumor 
angiogenesis in a murine breast cancer model.   
 Both the ultrasound methods successfully demonstrated images of the vasculature 
in tumors developed in a murine xenograft breast cancer model noninvasively at their 
respective transmit and receive frequencies, thus fulfilling the first specific aim of this 
study. The HF SHI (Tx: 24 MHz/Rx ~12 MHz) appears to be a better method than LF 
SHI (Tx: 8 MHz/ Rx: 4MHz) in monitoring angiogenesis non-invasively. It demonstrated 
the tumor images with weaker signals but higher resolution than LF SHI.  
Three immunohistochemical markers for angiogenesis that were taken into 
consideration were, Vascular endothelial growth factor (VEGF), Platelet endothelial cell 
adhesion molecule (PECAM or CD31) and Cyclooxygenase-2 (COX-2). The quantitative 
parameter, fractional tumor vascularity - derived from contrast enhanced high frequency 
subharmonic ultrasound images has been shown to provide a noninvasive measure of 
breast tumor neovascularity in rat xenograft models. The HF SHI images depicted in 
particular the expression of VEGF in the tumor specimens; albeit based on a limited 
sample size of 11 rats. The fractional vascularity obtained from HF SHI and LF SHI did 
not correlate with the FV for expression of CD31 and COX-2 respectively but the results 
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showed a trend towards significance for their expression. These results would be clearer 
for an increased sample size.  
6.2 Future work 
 The work presented in this study is based on a study conducted on a limited 
sample size. A large scale study with more rats and other breast cancer cell lines such as 
NMU mammary gland adenocarcinoma would provide more conclusive results for the 
expression of all the angiogenic markers in tumor. With an increased sample size, the 
results obtained for monitoring the expression of all the angiogenic markers (VEGF, 
CD31 and COX-2) over time by comparing the vascularity measures of rat tumors 
scanned on different days could be more conclusive.  
 Tumor angiogenesis is a key factor in the growth of tumor neovasculature and 
metastasis of the tumor, and hence anti-angiogenic treatment may be an effective way to 
cease the tumor growth. High frequency subharmonic imaging may become an important 
noninvasive tool for monitoring antiangiogenic therapies in breast tumor. Based on the 
conclusion for this study, there could be an expansion of this study further by studying 
the effects of VEGF inhibitor on the tumor neovascularity of murine xenograft breast 
cancer models using HF SHI technique.  
 In conclusion, HF SHI can be seen as a valuable diagnostic tool in monitoring 
angiogenesis of a breast tumor rat model and can even hold a great potential of 
monitoring the therapies related to antiangiogenic agents in small animals. These 
therapies could be further used pre-clinically for assessing breast cancer treatments.  
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APPENDIX 
 
Appendix 1: Cell culture protocol 
 
This protocol has been drafted in accordance to the thawing, propagating and 
cryopreserving protocol of NCI-PBCF-HTB26 (MDA-MB-231) Breast adenocarcinoma 
[67].  
Culture medium preparation: 
For a 500 ml bottle of DMEM 1x inject 56 ml of serum (10% of final volume) 
into the DMEM bottle. Inject 5.6 ml (1% of final volume) of penicillin streptomycin into 
the DMEM bottle. Swirl it to mix.  
Thawing and propagating cells: 
• Retrieve a vial of frozen cells. 
• Thaw the vial by gentle agitation in a water bath set at 35 °C to 37 °C. To reduce 
the possibility of contamination, keep the O-ring and cap out of the water.  
• Thaw the content with slight shake until only small ice is left in vial. Thawing 
should be rapid (approximately 2 min to 3 min, just long enough for most of the 
ice to melt).  
• Spray vial with 70% ethanol all over and wipe its surface with clean tissue in the 
hood. 
• Suspend the cells in fresh medium and transfer it to a petri dish.  
• Cells are cultured at 37°C in 5% CO2 and medium is changed about every 3 days.  
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• It usually takes about 2 days for cells to recovery from freezing. After cell culture 
reaches 80-85% confluence, subculture is conducted.  
 
Culturing the cells: 
Observe cells to see how confluent they are, whether the cells are alive, whether the 
medium hasn’t evaporated and whether the cells are not contaminated. After they reach 
80-85% confluence  
● Vacuum out all the media from the Petri dishes 
● Inject 2-3 ml of PBS into each Petri dish (to wash the cells).  
● Vacuum out the PBS of the Petri dishes.  
● These cells have a tendency to adhere to the walls of the petri dish while they 
were harvested. Hence to suspend them we use Trypsin. Injected 2-3 ml of 
Trypsin into each Petri dish and put the Petri dishes into incubator until the cells 
detach. 
● Use a pipette to measure an even number (e.g. 10 ml) of media and injected all the 
media measured into the first Petri dish to neutralize the trypsin/cell suspension. 
Then used the same pipette to remove the floating cells, Trypsin and media from 
the Petri dish and injected everything into the next Petri dish, repeated until 
pipette is full or all Petri dishes have been emptied.  
● Dispense everything from the pipette into a 50 ml centrifuge tube. Centrifugation 
makes it easy as to collected the cells from the dispense by separating them from 
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the rest of the media. Centrifuge (Damon/IEC Division CRU-5000 Centrifuge) – 
settings: 4°C, 10 minutes, 1000 rpm, break set to off. 
● Vacuum out all the media and Trypsin, leaving a small pellet of cells at the 
bottom of the centrifuge tube.  
● Inject (number of Petri dishes x 5 ml – not more than 6 or 7 Petri dishes at a time) 
ml of medium into the tube and redispense/remeasure until no cell pellets are left. 
If there is more than one tube, injected this mix into the next tube as well until no 
cell pellets are left in that tube. 
● Divide this mix evenly into an appropriate number of centrifuge tubes (reuse the 
tubes used in previous step) and then add medium to the tubes until the correct 
amount of media/cells are reached (5 ml per Petri dish). 
● Put Petri dishes into incubator and monitor the cell density daily. Incubator 
settings: 37°C and 5.0% CO2. 
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Appendix 2: Matlab functions and subroutines developed for data processing 
 
For reading encoded data from Sonix RP unit, a proprietary function RPead.m 
was obtained from Ultrasonix Research Forum (http://research.ultrasonix.com). This 
function loads the encoded data in the Matlab workspace as a variable.  
For reading the encoded data from Vevo 2100 unit a propriety C file, VsiExtract.c 
was obtained from Andrew Needles (Visual Sonics). Running this C file automatically 
saved the RF data files in csv format and images in jpeg format in the Windows Explorer.  
The functions and subroutines described below may be used to process the data 
further. 
	  
a.) Function: To show A-line spectrum of RF data. 
 
Input: The RF data files that were obtained from Vevo 2100 for each tumor injection as 
csv files were loaded in the Matlab Workspace.  
Output: The RF spectrum of each A-line (332) for the respective RF data file.   
function [spectrum_data,FFT_freq] =  Alinespectrum(data) 
data = data'; 
Fs = 400e6; 
FFT_freq = (0:8960-1)*(Fs/2)/8960;  
fft_plot = [];   
for i = 1:332 
     
    fft_data = 2*abs(fft(data(i,:),17920)); 
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    FFTdata = fft_data(1:end/2); 
    FFTdata = FFTdata'; 
    FFTdata = smooth(FFTdata); 
    FFTdata = FFTdata'; 
    figure(1) 
    plot(FFT_freq/10^6,(FFTdata)); 
    title(strcat('Aline No :',int2str(i))); 
    xlabel('Frequency (MHz)'); 
    ylabel('Amplitude'); 
    %hold on 
    if isempty(fft_plot) 
        fft_plot = (FFTdata); 
    else 
        fft_plot = [fft_plot;(FFTdata)]; 
    end 
    %saveas(gcf,['SmoothedAlines_',int2str(i),'_spectrum'],'jpg');   
   close all 
end 
  
fft_plot = mean(fft_plot); 
spectrum_data = fft_plot; 
figure(2) 
 plot(FFT_freq/10^6,(fft_plot)); 
     xlabel('Frequency (MHz)'); 
     ylabel('Amplitude'); 
end 
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b.)  Subroutine: To generate Maximum intensity projection image of an input 
ultrasound image of the tumor (of both LF SHI and HF SHI) and calculate the 
vascularity index of marked ROI in an ultrasound image.  
Input: An ultrasound image of the tumor in jpeg format 
Output: The MIP image of the input image with boundary of ROI (marked in green) and 
vascular areas (in red) and the value of fractional vascularity for the corresponding ROI 
in the Matlab command window.  
%% Clearing Workspace 
clear all; 
close all; 
  
%% Creating a filelist for accessing images 
disp('Creating a file list...') 
[filename, pathname] = uigetfile('*.*','Select FIRST image file...'); 
cd(pathname); 
files=dir('*.jpg'); 
filechar = double(filename); 
for it = 1:length(filechar) 
    if filechar(it) >= 48 & filechar(it) <= 57 
        break 
    end 
end 
if it >= length(filechar) 
    error('Error ** could not find number in filename.') 
end 
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tail = filename(length(filename)-3:length(filename)); 
numimages = 0; 
for ifilenum = 1:200 % Change this 200, if the number of jpegs in the folder exceeds 200 
    if exist(filename,'file') 
        numimages = numimages + 1; 
        filelist{numimages} = filename; 
    end 
    filename = [filename(1:it-1) num2str(ifilenum) tail]; 
end 
filelist = filelist'; % Output variable contains file list in sequential order 
  
%% MIP and Final image creation 
  
% Reading the first image and converting to grayscale 
img11=imread(filelist{1}); 
img11=im2double(rgb2gray(img11)); 
  
% Creating the final image after MIP 
[r,c]=size(img11); 
final_img=img11; 
  
disp('Creating the final image after MIP...') 
for k=1:max(size(filelist))-1 
    temp_image=imread(filelist{k+1}); 
    temp_image=im2double(rgb2gray(temp_image)); 
    for i=1:r % Implementation of MIP 
        for j=1:c 
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            if final_img(i,j)<temp_image(i,j) 
                final_img(i,j)=temp_image(i,j); 
            else 
            end 
        end 
    end 
    sprintf('File dealt with: %d',k+1) 
end 
  
% Display the final image after MIP and save it 
figure(1) 
imshow(final_img) 
title('MIP image without motion compensation') 
%saveas(gcf,strcat('Ver1_MIP_image_without_motion_compensation','.fig')) 
%saveas(gcf,strcat('MIP_image_without_motion_compensation','.jpg')) 
close all 
  
%% Selecting the region of the tumor 
[x,y,BW,xi,yi] = roipoly(final_img); % The user has to define the polygon 
  
%% Calculating vascularity index in the tumor 
% This is defined as the total number of non-black pixels divided by the 
% total number of pixels in the region corresponding to the tumor 
tumor_pixels_structure=regionprops(BW, 'PixelList'); 
 % Pixels from the final MIP image corresponding to the tumor 
tumor_pixels=tumor_pixels_structure.PixelList; 
number_of_tumor_pixels=max(size(tumor_pixels)); 
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% Pixel Values of the original image corresponding to the tumor 
for i=1:number_of_tumor_pixels 
    row_number=tumor_pixels(i,2); 
    col_number=tumor_pixels(i,1); 
    pixel_value_tumor_region(i)=final_img(row_number,col_number); 
end 
% Pixels including vascular component should have higher pixel values 
% relative to the tumor background - threshold for tumor background is used 
number_of_vascular_pixels=0; 
counting_threshold=graythresh(pixel_value_tumor_region); 
% Counting the number of pixels corresponding to vascularity 
for i=1:number_of_tumor_pixels 
    if pixel_value_tumor_region(i) > counting_threshold; 
        number_of_vascular_pixels=number_of_vascular_pixels+1; 
    else 
    end 
end 
% Calucluating and displaying the vascularity index 
vascularity_index=number_of_vascular_pixels/number_of_tumor_pixels; 
percent_vascularity_index=vascularity_index*100; 
sprintf('Vascularity index with threshold %f is : 
%d',counting_threshold,vascularity_index) 
sprintf('Percent Vascularity index with threshold %f is : 
%d',counting_threshold,percent_vascularity_index) 
  
% To color code and show the identified vascular pixels in the final image 
% which were used for vascularity index calculation - visual verification 
loc=find(pixel_value_tumor_region>counting_threshold); 
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vascular_pixel_locations=tumor_pixels(loc,:); 
figure(2) 
imshow(final_img) 
hold on 
plot(vascular_pixel_locations(:,1),vascular_pixel_locations(:,2),'.r') 
plot(xi,yi,'--g', 'LineWidth',3) 
hold off 
title('MIP image without motion compensation_vascular_areas') 
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Appendix 3: List of Statistical tests used  
 
 
 
Wilcoxon’s signed rank test:  
Wilcoxon’s signed rank test was used to compare the mean scores of images filtered 
using three Bandpass filters. The filters were implemented on the images acquired at the 
time point of maximum contrast mean power during an entire injection. All the images 
were scored on a visual analogue scale of 1 to 5.  
 
 
Linear Regression Analyses:  
Linear Regression was used to compare the fractional vascularities per ROI obtained 
using two ultrasound methods (HF SHI and LF SHI) and pathological specimens stained 
for VEGF, CD 31 and COX-2. Each of the comparisons yielded respective r values and 
significant p values.  
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Appendix 4: List of software used  
 
 
 
 
1.  Matlab R 2013a (The Mathworks Inc., Natick WA) 
Purpose: To acquire and process RF ultrasound data. License: Drexel University  
 
 
2.  IBM SPSS 20 (IBM Corporation, Armonk NY) 
Purpose: For statistical analyses. License: Drexel University  
 
 
3. Microsoft Office 2010 (Microsoft Corporation, Redmond, WA) 
Purpose: For record keeping, publishing and presentations. License: Drexel University 
 
 
4. Endnote (Thomas Reuters, New York, NY) 
Purpose: For managing and publishing bibliographies. License: Drexel University 
 
 
 
	  
